Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
📢 “Data speaks, and bringing the data into the clinic helps me.” – Dr. Christina Charles-Schoeman
Hear her discussion with Dr. Manish Jain about how SELECT-SWITCH informs clinical practice. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/ni7IdVFobf https://t.co/jAvAVmAvUa
Dr. John Cush @RheumNow ( View Tweet)
New, Advanced Therapies in Gout
https://t.co/7i6936H7ZS https://t.co/8oOzqVKLGF
Dr. John Cush @RheumNow ( View Tweet)
2026 BSR Pain Guideline: What Rheumatologists Need to Know
The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.
https://t.co/3Jtneox8Rh https://t.co/06ccLhjhMh
Dr. John Cush @RheumNow ( View Tweet)
Updated Guidance for Artificial Intelligence Use in Medical Publications
JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. https://t.co/irid5koIjo
Dr. John Cush @RheumNow ( View Tweet)
NHANES survey (2005-2018) studied prevalence of arthritis in adults w/ depression (PHQ-9 ≥10), From 15157 depressed pts, RA was most prevalent & increased 7.8 to 17.7%; OA unchanged 11.7 to 10.7% & PsA declined 7.2 to 1.7%. Depression assoc w/ higher risk for RA (OR 1.40) & PsA https://t.co/fcROEvsHDT
Dr. John Cush @RheumNow ( View Tweet)
2026 PGY1 match for non–US citizen international medical graduates (IMGs) has reached a 5-year low; yet US health care relies heavily on non–US-born MDs. In US, there are 6300 Rheumatologists - 46.9% US born USMG; 5.4% US born IMG; 11.2% non-US born USMG; 36.5% non-US born IMG https://t.co/cwx5ugBaVE
Dr. John Cush @RheumNow ( View Tweet)
ZEUS Trial: IL-6 Inhibition Fails to Cut Cardiovascular Events
The phase 3 ZEUS trial (published in JAMA Dec. 2025) tested the IL-6 ligand inhibitor ziltivekimab in over 6,000 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated hsCRP—a population enriched for an inflammatory driver of risk.
Read Article
Biomarker substudy from SENSCIS trial of nintedanib in SSc-ILD shows higher baseline KL-6 levels >1000 U/mL was assoc w/ greater FVC worsening; & decrease in CA-125 was assoc. w/ nintedanib responses. Epithelial cells are primary source of CA-125 in the lung https://t.co/7VJ2UDOKin
Dr. John Cush @RheumNow ( View Tweet)
Evaluating Inflammatory Joint Pain in Older Adults
Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for Primary Care Clinicians (PCCs), the tenets and https://t.co/TPKEOjkcKl
Dr. John Cush @RheumNow ( View Tweet)
Wealth and Where you Live Influences Outcomes
Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and https://t.co/MyzWRx580R
Dr. John Cush @RheumNow ( View Tweet)
Survey: Upgrading & Maximizing the Classics (Urate Lowering Therapies, etc)
https://t.co/w6uzIlaeG7 https://t.co/HW09DVrMed
Dr. John Cush @RheumNow ( View Tweet)
What's New in Lyme Disease
JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.
https://t.co/jG09wc6gI8 https://t.co/rQBW6RIz5U
Dr. John Cush @RheumNow ( View Tweet)
2026 BSR Pain Guideline: What Rheumatologists Need to Know
The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.
Read Article
"Be so good they can't ignore you." - Steve Martin https://t.co/lMRAY57rW9
Dr. John Cush @RheumNow ( View Tweet)
POETYK PsA-1: Deucravacitinib in Biologic-NaĂŻve PsA
POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0
Dr. John Cush @RheumNow ( View Tweet)
Study of 364 Japanese myositis (IIM) pts - 42 (11.4%) had cancer-assoc myositis (CAM); 30/42 Dx w/in ±1 yr of IIM. CA risk incr ±3 yrs of IIM (SIR 2.54), highest 1st yr (SIR 8.66). 5 factors predicted CAM: TIF1γ +, ^CRP, dermatomyositis, older age, +FHx CA (AUC 0.86; sensitivity https://t.co/9ojTWTK5kO
Dr. John Cush @RheumNow ( View Tweet)
Congratulations to Dr. Edoardo Cipolletta (U Nottingham) - winner of Gout, Urate, and Crystal Deposition Disease Best PhD Thesis Award. Read his insightful interview on his reasearch on #gout. https://t.co/5i3hEV6PJX https://t.co/XV5trvEonW
Dr. John Cush @RheumNow ( View Tweet)
Substudy of 131 Still’s dz pts from the Autoinflammatory Dz (AIDA) registry. 38% underdosed w/ canakinumab (CAN) vs 62% appropriately dosed (300 mg q4wks or 4 mg/kg). Underdosed CAN had lower odds of long-term remission & D/C CAN (3.9% vs 19%) https://t.co/l94zB9NkKv https://t.co/D8FNUXS0nv
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Doubting RS3PE (8.14.2026)-
Mentshlichkeit (8.7.2026)
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
TU: Systemic Burden of Gout Part 2 (24 plus)
Therapeutic Updates
Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Drs. Elizabeth Volkmann and Robert Suh explore the roles rheumatologists and radiologists play in diagnosing and monitoring autoimmune ILD and hear from a patient about her experience.
Read Post
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026.
Read Post
Poster Hall
